our Premium Content: News alerts, weekly reports and conference planners

GENE:

CSF3R (Colony Stimulating Factor 3 Receptor)

News alerts, weekly reports and conference planners

CSF3R signalling beyond granulopoiesis: new paradigms in female reproductive biology. (PubMed, Cytokine)

G-CSF therapy has also shown benefits in improving endometrial receptivity in select cases of reproductive failure. This review explored CSF3R biology, signalling, disease involvement, and therapeutic potential, positioning G-CSF3R as an emerging, actionable node in reproductive medicine and gynaecologic oncology.

2 days ago

Review • Journal

CSF3R (Colony Stimulating Factor 3 Receptor)

14d

Thymoquinone decreases cell proliferation and immune evasion of breast cancer cells by reducing CD55 and CD114 levels. (PubMed, Med Oncol)

Therefore, restoring immune recognition and inhibition of proliferation. Hence, thymoquinone could be a potent target for breast cancer therapeutics.

14 days ago

Journal

CSF3R (Colony Stimulating Factor 3 Receptor) • SOX2 • CD14 (CD14 Molecule) • NANOG (Nanog Homeobox) • CD55 (CD55 Molecule)

From mutational signatures to practice: Artificial intelligence-guided repurposing for blast crisis chronic myeloid leukemia. (PubMed, World J Clin Oncol)

Prospective registries and trial enrollment should test signature-defined micro-cohorts with versioned and auditable reporting. These mappings are designed to provide hypotheses and depend on independent functional validation, prioritizing safety in combination methods with tyrosine kinase inhibitors, and allows for practical implementation in rapid turnaround environments.

1 month ago

Journal

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CSF3R (Colony Stimulating Factor 3 Receptor)

3ms

Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. (PubMed, Br J Cancer)

Our AI model, using only archival histologic slides, accurately predicted postoperative recurrence in PDAC and revealed image features linked to outcomes and gene expression.

3 months ago

Journal

CSF3R (Colony Stimulating Factor 3 Receptor) • IGFBP3 (Insulin-like growth factor binding protein 3)

4ms

CSF3R Mutations Imply Adverse Prognostic Impact in Adult Acute Myeloid Leukemia Patients: A Single-Center Retrospective Study. (PubMed, Cancer Med)

CSF3R mutations define a distinct, high-risk AML subset characterized by an inferior treatment response and survival, warranting incorporation into future risk stratification.

4 months ago

Retrospective data • Journal

NPM1 (Nucleophosmin 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • CSF3R (Colony Stimulating Factor 3 Receptor) • CEBPA (CCAAT Enhancer Binding Protein Alpha)

NPM1 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation

4ms

Development and validation of a cell-based methodology to evaluate filgrastim relative affinity to granulocyte colony-stimulating factor receptor. (PubMed, J Immunoassay Immunochem)

After performing a validation exercise, the method proved to be accurate, specific, and linear within an affinity interval of 75 to 130%; precise with a confidence interval of 93.6 to 114.2% and a coefficient of variation of 12.6%. The validation exercise proved that the proposed cell-based method is a viable alternative to evaluate the biological activity of filgrastim via the affinity for its receptor and it is suitable to be included as part of its biological characterization exercises as well as in comparability exercises for products coming from distinct manufacturing processes.

4 months ago

Journal

CSF3R (Colony Stimulating Factor 3 Receptor)

Neupogen (filgrastim)

4ms

LAX1 as a core biomarker in Alzheimer's disease and periodontitis via the STAT signaling pathway. (PubMed, BMC Geriatr)

LAX1 gates STAT-dependent neuroinflammation and periodontal destruction, offering a druggable checkpoint and blood-based biomarker for these convergent chronic diseases.

4 months ago

Journal

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CSF3R (Colony Stimulating Factor 3 Receptor) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta)

4ms

Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis. (PubMed, Br J Haematol)

This work provides the first genomic characterisation of a diagnosed MDS cohort in China and establishes the first risk prediction model for MDS-to-AML transformation, alongside novel prognostic models for OS and PFS. These tools offer improved prognostic prediction and potential guidance for therapeutic strategies in Chinese patients with MDS.

4 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • ETV6 (ETS Variant Transcription Factor 6) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • CSF3R (Colony Stimulating Factor 3 Receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • STAG2 (Stromal Antigen 2) • GATA2 (GATA Binding Protein 2) • CALR (Calreticulin)

TP53 mutation • SRSF2 mutation • STAT3 mutation

4ms

Efficacy and Safety of Pegfilgrastim in Patients With Severe Congenital Neutropenia. (PubMed, EJHaem)

Larger studies are warranted to evaluate its long-term safety and efficacy. This trial is registered at https://irct.behdasht.gov.ir/ in Iranian Registry of Clinical Trials (IRCT) # IRCT20150125020786N3.

4 months ago

Journal

RUNX1 (RUNX Family Transcription Factor 1) • CSF3R (Colony Stimulating Factor 3 Receptor)

Neulasta (pegfilgrastim)

4ms

Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options. (PubMed, Hemasphere)

The most used agents include hydroxyurea, interferon, hypomethylating agents, and JAK inhibitors, although none of them are disease-modifying. Allogeneic hematopoietic stem cell transplant remains the only potentially curative approach and should be considered in all eligible patients. Actionable mutations (CSF3R, NRAS/KRAS, and KIT) have also been identified, supporting the development of new agents targeting the involved pathways.

4 months ago

Review • Journal

KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • CSF3R (Colony Stimulating Factor 3 Receptor) • SETBP1 (SET Binding Protein 1) • ETNK1 (Ethanolamine Kinase 1)

KRAS mutation • NRAS mutation • KIT mutation • ASXL1 mutation • TET2 mutation • EZH2 mutation • CBL mutation • SRSF2 mutation

hydroxyurea

4ms

Case Report: Blood single-cell analysis of a IVB high-grade serous ovarian cancer patient presenting a favorable prognosis. (PubMed, Front Oncol)

This integrative molecular and phenotypic profiling of blood-derived components identified potentially distinct molecular signatures, such as overexpression of IL12, ANGPT1 downregulation and HIF1A downregulation, in the literature described as linked to the patient's beneficial prognosis. These findings suggest that advanced liquid biopsy techniques may provide complementary insights into prognostic biomarkers and therapeutic targets in HGSOC.

4 months ago

Journal

AKT1 (V-akt murine thymoma viral oncogene homolog 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CSF3R (Colony Stimulating Factor 3 Receptor) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • DDIT4 (DNA Damage Inducible Transcript 4) • PGK1 (Phosphoglycerate Kinase 1)